What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024
This mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from first-gener...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.23.176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from first-generation therapies such as midostaurin to second-generation agents such as gilteritinib, crenolanib and quizartinib. Midostaurin, the first FLT3-targeting therapy approved for newly diagnosed *FLT3*-mutated AML, laid the foundation for FLT3 inhibition by demonstrating survival benefits when combined with chemotherapy. Gilteritinib has emerged as a standard for relapsed/refractory (R/R) AML, crenolanib shows efficacy in post-transplant maintenance and quizartinib demonstrates promise in reducing frontline relapse risk. These advancements have improved outcome of *FLT3*-mutated AML in recent years while emphasizing the need for ongoing innovation to tackle relapse and resistance.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland
One anonymous peer reviewer
Received on December 20, 2024; accepted after peer review on March 07, 2025; published online on March 10, 2025. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |